Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MATCH Subprotocol A: Afatinib in EGFR-mutated Solid Tumors or Lymphomas
NCT06385483Phase 2Active, not recruiting
- Sponsor
- National Cancer Institute
- Start
- Feb 2018
- Primary completion
- Dec 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of afatinib in lymphoma, solid tumor, multiple myeloma (MM), sponsored by National Cancer Institute. Started Feb 2018; status: active, not recruiting.
02
Drugs
afatinib
03
Conditions
lymphomasolid tumormultiple myeloma (MM)
Beyond the preview
Go deeper on NCT06385483.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06385483.